Roche’s recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.
FDA seeks to encourage fewer animal studies with new draft guidance
The FDA unveiled long-awaited draft guidance on how biopharma companies can validate new approaches for toxicology and other early-phase safety studies, potentially reducing the animal


